Short Interest in DexCom, Inc. (NASDAQ:DXCM) Decreases By 7.7%

DexCom, Inc. (NASDAQ:DXCM) saw a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 8,420,000 shares, a decline of 7.7% from the November 15th total of 9,120,000 shares. Based on an average daily trading volume, of 4,170,000 shares, the short-interest ratio is presently 2.0 days.

DexCom Stock Down 1.0 %

DXCM traded down $0.78 during trading on Monday, hitting $76.41. The company had a trading volume of 4,013,183 shares, compared to its average volume of 3,884,968. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company has a market cap of $29.85 billion, a PE ratio of 46.22, a P/E/G ratio of 2.46 and a beta of 1.12. The business has a 50-day moving average of $73.76 and a 200-day moving average of $84.04.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

A number of institutional investors have recently modified their holdings of the stock. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom in the second quarter valued at about $25,000. Sachetta LLC lifted its holdings in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares during the last quarter. Riverview Trust Co grew its position in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares in the last quarter. DT Investment Partners LLC increased its holdings in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC acquired a new stake in shares of DexCom during the 3rd quarter valued at approximately $57,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on DXCM shares. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Oppenheimer decreased their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. raised their price objective on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Wells Fargo & Company upped their target price on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Sanford C. Bernstein increased their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $98.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.